Key facts
- This page summarizes Sara Nochur's Form 4 filing for MARINUS PHARMACEUTICALS, INC..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Jun 2024, 16:26.
Sara Nochur - 18 Jun 2024 Form 4 Insider Report for MARINUS PHARMACEUTICALS, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 18 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Jun 2024, 16:26:04 UTC
- Prior SEC filing
- 19 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Debra A. Mohollen, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sara Nochur filed Form 4 for MARINUS PHARMACEUTICALS, INC. on 20 Jun 2024.
Change
- Previous filing in this sequence was filed on 19 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,300
- Change %
- +21%
- Price
- $0.000000
- Shares after
- 13,250
- Date
- 18 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +10,450
- Change %
- Price
- $0.000000
- Shares after
- 10,450
- Date
- 18 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,450
- Exercise price
- $1.40
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the grant of restricted stock units (RSUs). The RSUs vest in full on July 15, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.
Footnote F2
The option vests and becomes exercisable in full on July 15, 2025, subject to the reporting person's continued service with the Issuer.